Reported results
- Net loss for the three months ended September 30, 2026 was $6.2 million, or $(0.21) per basic and diluted share, compared to $1.9 million, or $(0.07) per basic and diluted share, for the three months ended September 30, 2025.
- Cash and cash equivalents as of September 30, 2026 were $10.4 million ($10,363,975), compared to $5,076,144 as of December 31, 2025.
- General and administrative expenses for the three months ended September 30, 2026 were $1.4 million ($1,379,245), compared to $1.8 million ($1,754,856) for the three months ended September 30, 2025.
- Research and development expenses for the three months ended September 30, 2026 were $0.6 million ($605,197), compared to $0.2 million ($158,699) for the three months ended September 30, 2025.
- Loss from operations for the three months ended September 30, 2026 was $1,984,442, compared to $1,913,555 for the three months ended September 30, 2025.
Guidance
- The company expects its available cash to fund operations into the third quarter of 2027.
- Turn Therapeutics expects to report topline results from the Phase 2b trial in the first quarter of 2027.
- Patient enrollment in the planned Phase 2a trial of GX-03 for hidradenitis suppurativa is expected to begin in the first quarter of 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.
